Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Baxter Oncology GmbH violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

What happens after a Form 483 is issued?

The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.

FDA Form 483 — Baxter Oncology GmbH (September 26, 2025)

Here's the summary: FDA inspected Baxter Oncology GmbH in Germany and issued a Form 483 listing 1 inspectional observation following an inspection that concluded 2025-09-26. FDA records classify Baxter Oncology GmbH as a drug manufacturer. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	Baxter Oncology GmbH
FEI / inspection ID	3002806419
Inspection end date	September 26, 2025
Citation count	1

Citations explained

Observation 1 — Procedures designed to prevent microbiological contamination of dmg products purp01ting to be

Procedures designed to prevent microbiological contamination of dmg products purp01ting to be sterile are not established and fo llowed. 4 1. Aseptic behavior procedure SOP-01007, which describes avoiding reaching the (bH > over sterile -----surfaces and open container s, was not fo llowed. For example: 4 a. On September 23, 2025, at aer.roximately 10:13 am, while fillin 7atch {Cb>< > we observed an operator on 4 CbH > Line, using non-ste1ile Cb>C4> to operate the Cb)<4> reacfi over exposed vials which were later 1 fifled and not rejected. On September 26, 2025, at • --...'"' dming the fillin g_Qf_batc h we obse1ved our 4 or using the non-sterile faulty <bX > --i. During t e mte1vention the 4 reached over the newly . __ d '(bH 4 > already installed sterile CbH > -- c. Durin~ set-up of the aseptic filling line for on September 19, 2025, the operators used the (b <-O directly above the exposed ____ _. 4.

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Baxter Oncology GmbH’s FDA history

Argus HQ has recorded 1 total FDA action tied to Baxter Oncology GmbH: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator's written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Baxter Oncology GmbH violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
What happens after a Form 483 is issued?: The firm typically has 15 business days to submit a written response describing planned corrections. FDA reviews that response, and unresolved or serious findings can lead to a Warning Letter, import alert, or other enforcement action, though many 483s are resolved without further FDA action.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for Baxter Oncology GmbH

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2025). FDA Form 483 — Baxter Oncology GmbH (September 26, 2025) — 1 Citations. Digital Empire LLC. Retrieved from https://argushq.ai/483/fda-483-baxter-oncology-gmbh-2025-09-26-3002806419

MLA

"FDA Form 483 — Baxter Oncology GmbH (September 26, 2025) — 1 Citations." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/483/fda-483-baxter-oncology-gmbh-2025-09-26-3002806419.

Chicago

Argus HQ Research. "FDA Form 483 — Baxter Oncology GmbH (September 26, 2025) — 1 Citations." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/483/fda-483-baxter-oncology-gmbh-2025-09-26-3002806419.

BibTeX

@misc{argushq_argushq_ai_483_fda_483_baxter_oncology_gmbh_2025_09_26_3002806419_2025,
  title = {FDA Form 483 — Baxter Oncology GmbH (September 26, 2025) — 1 Citations},
  author = {{Argus HQ Research}},
  year = {2025},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/483/fda-483-baxter-oncology-gmbh-2025-09-26-3002806419},
  note = {Accessed: July 15, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗